Thursday, August 25, 2016

Oramed hopes to start Phase 3 oral insulin trial next year

Oramed hopes to start Phase 3 oral insulin trial next year

August 23, 2016 by · Leave a Comment 

Tweet After posting positive Phase 2b results with its oral insulin drug candidate, ORMD-0801 in Type 2 diabetes, Oramed Pharmaceuticals (NASDAQ:ORMP) hopes to meet with the FDA before the end of 2016 to discuss proceeding with a Phase 3 clinical trial in 2017. “We believe that our data set shows that oral insulin works, which […]

In conversation with Ben Haynor

In conversation with Ben Haynor

August 16, 2016 by · Leave a Comment 

Tweet As a senior research analyst with Feltl & Co. for the past six years, Ben Haynor ranked second in the May 2013 Wall Street Journal Best on the Street publication in the Medical Equipment and Supplies category and was named the top stock picker in U.S. Health Care Equipment and Supplies in StarMine’s 2013 […]

Parvus developing Navacims to treat autoimmune diseases

Parvus developing Navacims to treat autoimmune diseases

August 9, 2016 by · Leave a Comment 

Tweet Closely-held Parvus Therapeutics is developing a broad therapeutic platform, called Navacims, to treat autoimmune diseases through in vivo expansion and activation of disease-specific regulatory T-cells (T-regs), which normally play a key role in maintaining immune system balance and immune tolerance. “We have extensive preclinical proof-of-concept data, with in vivo reversal of disease in mouse […]

Oramed gets additional milestone from HTIT

Oramed gets additional milestone from HTIT

August 2, 2016 by · Leave a Comment 

Tweet Oramed Pharmaceuticals (NASDAQ:ORMP) has received a milestone payment of $4-million from Hefei Tianhui Incubator of Technologies (HTIT) of China. The milestone is part of a license and investment agreement between Oramed and HTIT, and follows Oramed’s report of additional positive efficacy and safety data from a recently completed Phase 2b trial of its oral […]

Tandem expands pediatric indication of insulin pump

Tandem expands pediatric indication of insulin pump

July 26, 2016 by · Leave a Comment 

Tweet Tandem Diabetes Care (NASDAQ:TNDM) received FDA clearance of an expanded pediatric indication for the t:slim Insulin Pump, lowering its use to children age 6 and older from children age 12 and older. The t:slim Pump is the first and only touchscreen insulin pump cleared by the FDA. The expanded pediatric indication applies to the […]

BTIG starts Insulet, Intersect at neutral

BTIG starts Insulet, Intersect at neutral

July 13, 2016 by · Leave a Comment 

Tweet BTIG Research initiated research of Insulet (NASDAQ:PODD) and Intersect ENT (NASDAQ:XENT) with “neutral” ratings. Shares of Insulet closed at $32.21 and shares of Intersect at $13.51 on Tuesday. Analyst Sean Lavin writes that he sees Insulet’s core business as fairly valued at five times next 12 months revenue as both the major upside events […]

Antibe to have Phase 2 pain data by third quarter

Antibe to have Phase 2 pain data by third quarter

June 21, 2016 by · Leave a Comment 

Tweet Antibe Therapeutics (OTCQB:ATBPF; TSX-V:ATE) expects to have data by the third quarter this year from a small Phase 2 study of its naproxen derivative, ATB-346, in patients with osteoarthritis in the knee. “ATB-346 was designed to deliver non-addictive pain relief with significantly less gastrointestinal and cardiovascular damage than is typically associated with the use […]

Lipocine advancing pipeline, PDUFA for oral TRT

Lipocine advancing pipeline, PDUFA for oral TRT

May 31, 2016 by · Leave a Comment 

Tweet With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are advancing towards Phase 3 ready status this year. “We have a robust pipeline with a number of key milestones in 2016 besides the decision on […]

Delivra implementing U.S. expansion strategy for topical creams

Delivra implementing U.S. expansion strategy for topical creams

May 24, 2016 by · Leave a Comment 

Tweet The major initiative for Delivra (TSX-V:DVA) in 2016 is to introduce its flagship LivRelief topical pain and nerve creams to the U.S. market, initially through a U.S. web store and Amazon, and then through regional and national retailers, such as Walmart, Walgreens and CVS. “We are launching an aggressive digital campaign shortly, and later […]

Rodman starts LabStyle Innovations at buy

Rodman starts LabStyle Innovations at buy

May 9, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of LabStyle Innovations (NASDAQ:DRIO) with a “buy” rating and $12 price target. The stock closed at $5.40 on Friday. LabStyle is an emerging digital health company focused on the monitoring and management of diabetes. Analyst Raghuram Selvaraju writes that the company has developed an integrated system to enable […]

Next Page »

Email Newsletters with Constant Contact
Google+